Nausea and vomiting are common symptoms that can cause enormous misery for cancer patients, undermining quality of life and contributing to weakness, anorexia and nutritional problems. 1 Evidence-based recommendations for the management of treatment-induced emesis are available, but the management of nausea arising as a consequence of the disease itself is less well researched. This article summarises palliative care guidelines derived from animal models and validated in a range of human studies. 2,3
The vomiting centre (VC) in the brainstem integrates all the components of the reflex, resulting in nausea, salivation, pallor, sweating, retching, protective closure of the glottis and vomiting. The VC receives sensory input from autonomic nerves; stretch receptors on these nerve terminals detect distortion such as liver capsule stretch by metastatic disease, peritoneal distortion by para-aortic lymphadenopathy or bowel dilatation due to obstruction or constipation. Afferents include the vagus, sympathetic trunk and glossopharyngeal nerve. The VC also receives input from higher centres, for example, fear, pain and memory.
Choosing an anti-emetic
With knowledge both of the central pathways that mediate nausea and vomiting and of the neuroreceptors involved, it is possible to select specific receptor antagonist drugs as anti-emetics. 5 The efficacy of a drug as an anti-emetic is proportional to its binding affinity for its receptor. 6 The more selective the binding of a drug, the fewer its side effects. Relative binding affinities are summarised in • Serotonin-3 (5HT 3 ) receptor antagonists are widely overprescribed. They are effective for early emesis induced by chemotherapy or during radiotherapy across the gastrointestinal tract (eg low thoracic spine, total body irradiation) but probably have no role in other types of nausea caused by cancer. Constipation is a major side effect of this class of drugs.
• Neurokinin-1 (NK1) receptor blockers are effective anti-emetics. NK1 receptors are widely distributed in the brain. An oral NK1-receptor antagonist is licensed for use in chemotherapy-induced nausea; its role in palliative care has yet to be explored.
Non-pharmacological measures
Attention should be paid to mood and morale, reducing exposure to strong cooking smells and providing small, palatable meals. Carbohydrate meals are often better tolerated; sour flavours may be preferred by some patients (eg citrus sorbets, lemon drinks).
Psychological techniques to palliate nausea due to advanced disease have not been systematically studied, but studies of relaxation using progressive muscle relaxation and guided mental imagery in chemotherapy patients have shown that the stress of treatment-related nausea can be reduced by these methods.
Acupuncture and acupressure have demonstrated useful anti-emetic effects for chemotherapy-related and postoperative nausea and vomiting; the effect of acupuncture can be prolonged by acupressure; transcutaneous nerve stimulation at acupuncture points is also effective. 9, 10 There are no studies of acupuncture in a palliative care setting, although individual case reports suggest it can be a successful strategy.
End-of-life care
As the end of life approaches, taking oral medications can be a burden. All the anti-emetics recommended in Table 1 7 and require medical palliation.
Cyclizine 50 mg tds sc or per rectum to block VC activity. Haloperidol 1.5-3 mg sc daily in addition, if nausea persists. Once nausea is controlled, oral dosing is effective.
Consider:
Anticholinergic agents (hyoscine butylbromide 40-120 mg/day or glycopyrrolate 0.1-0.2 mg tds sc) or octreotide 200-1,000 µg/day 8 can be used as antisecretory agents and will also relax smooth muscle, thus reducing colic. High-dose corticosteroids may help to reduce pressure and restore patency in malignant bowel obstruction, at least temporarily (eg dexamethasone 12-16 mg daily). 9 Correction of dehydration may reduce symptoms. 8 The use of nasogastric tubes and prolonged intravenous fluids is unnecessary; nasogastric tubes may aggravate nausea by glossopharyngeal stimulation and vigorous rehydration will enhance intraluminal secretion of fluid, increasing pressure, colic and nausea.
Patients can eat and drink for pleasure; they should be warned to expect intermittent mechanical vomits, although it should be possible to control nausea.
Ureteric obstruction
Triggers to nausea: ureteric stretch stimulates VC uraemia stimulates CTZ toxic drug accumulation due stimulates CTZ to reduced renal clearance Management:
Ureteric stenting will palliate both stretch and chemical stimulation of nausea, but is not always possible. Cyclizine 50 mg tds sc or per rectum to block VC activity. Haloperidol 1.5-3 mg sc daily in addition, if there is renal insufficiency. Doses of renally-excreted drugs will also need to be modified.
Gastric stasis
Gastric emptying may be delayed by anticholinergic drugs, increased intra-abdominal pressure or compression of the gastric outlet.
Symptoms: Stretching of the stomach by ingested food, drink and air, and by gastric secretions causes distortion of the oesophageal sphincter. This permits acid reflux causing heartburn, whilst the distending stomach irritates the diaphragm causing hiccups. Eating or drinking, even small volumes, when the stomach is already full induces early satiation accompanied by a sensation of bloating. The stomach has great capacity for stretch, and so nausea is not a feature until overstretching occurs; there is often a short period of premonitory nausea, followed by large-volume vomiting which completely relieves all the other symptoms.
Management:
Treatment is most effective when directed at the cause (eg stopping any anticholinergic drugs or tapping ascites). Prokinetic agents (metoclopramide, domperidone) can restore peristalsis and reduce reflux. Proton-pump inhibitors reduce the volume and acidity of gastric secretions.
Patients should be encouraged to eat little and often.
In duodenal or high jejunal obstruction, prokinetic drugs may cause colic. The volume of pancreatic and mucosal secretion can be reduced using anticholinergic drugs and/or octreotide (see above); if frequency of vomiting remains intolerable, the use of a venting PEG should be considered for palliation. CTZ = chemoreceptor trigger zone; PEG = percutaneous endoscopic gastroscopy; sc = subcutaneously; VC = vomiting centre.
problem with cyclizine which can be given as a suppository instead. Anticipating the terminal phase and making appropriate adjustments in route of administration of those drugs essential to maintaining comfort are important parts of the cancer team's work. The Liverpool Care Pathway for the dying patient is a national framework for excellent end-of-life care (more information is available from www.lcp-mariecurie.org.uk).
Conclusions
Cancer-related nausea and vomiting may be a presenting symptom of curable disease or a burden of advanced disease. In either case, it is possible to palliate the symptoms by applying a knowledge of the pathways that mediate emesis and selecting anti-emetic drugs on the basis of their site of action. Other diseasemodifying treatments, if available, can proceed in parallel with palliation of nausea and vomiting. Good palliation of these distressing symptoms can be achieved and should be the aim of care for nauseated patients.
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